Stock Analysis on Net

Allergan Inc. (NYSE:AGN.)

This company has been moved to the archive! The financial data has not been updated since February 19, 2015.

Balance Sheet: Liabilities and Stockholders’ Equity 

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Allergan Inc., consolidated balance sheet: liabilities and stockholders’ equity

US$ in thousands

Microsoft Excel
Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Notes payable 72,100 55,600 48,800 83,900 28,100
Convertible notes 642,500
Accounts payable 287,400 283,200 233,100 200,400 222,500
Accrued compensation 292,800 269,100 223,700 200,600 182,400
Sales rebates and other incentive programs 372,100 279,300 270,600 249,100 186,500
Royalties 27,300 26,200 26,000 27,000 34,600
Interest 22,000 22,000 18,200 15,000 17,300
Sales returns, specialty pharmaceutical products 60,400 56,500 50,000 37,300 29,200
Legal settlement expenses 15,200
Product warranties, breast implant products 7,700 7,600 6,700 6,500 6,700
Contingent consideration 53,800 9,900 59,000 4,900
Investment bank advisory fees 24,000
Annual branded prescription drug fee 34,100 6,100
Restructuring charges 109,600
Other 194,000 189,900 159,100 130,300 147,300
Other accrued expenses 905,000 597,500 589,600 470,100 436,800
Income taxes 38,900 16,100
Current liabilities 1,557,300 1,244,300 1,095,200 955,000 1,528,400
Long-term debt, excluding current maturities 2,085,300 2,098,300 1,512,400 1,515,400 1,534,200
Postretirement benefit plan 56,500 44,300 46,600 41,300 56,500
Qualified and non-qualified pension plans 267,300 194,500 218,300 204,400 152,100
Deferred executive compensation 116,300 105,300 85,300 75,000 68,900
Deferred income 72,800 67,000 75,100 81,100 87,800
Contingent consideration 312,100 215,300 165,300 209,700 41,300
Product warranties, breast implant products 28,500 26,000 27,700 26,100 23,400
Unrecognized tax benefit liabilities 82,600 67,700 53,800 39,300 15,900
Other 74,000 42,100 37,000 28,900 18,500
Other liabilities 1,010,100 762,200 709,100 705,800 464,400
Non-current liabilities 3,095,400 2,860,500 2,221,500 2,221,200 1,998,600
Total liabilities 4,652,700 4,104,800 3,316,700 3,176,200 3,527,000
Preferred stock, $.01 par value; none issued
Common stock, $.01 par value 3,100 3,100 3,100 3,100 3,100
Additional paid-in capital 3,353,700 3,032,800 2,900,600 2,761,800 2,815,500
Accumulated other comprehensive loss (408,600) (226,600) (244,600) (241,400) (152,900)
Retained earnings 5,894,800 4,646,700 3,832,100 2,969,300 2,225,900
Treasury stock, at cost (1,090,000) (992,800) (654,100) (183,200) (133,900)
Total Allergan, Inc. stockholders’ equity 7,753,000 6,463,200 5,837,100 5,309,600 4,757,700
Noncontrolling interest 10,000 6,300 25,500 22,800 23,400
Total equity 7,763,000 6,469,500 5,862,600 5,332,400 4,781,100
Total liabilities and equity 12,415,700 10,574,300 9,179,300 8,508,600 8,308,100

Based on: 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Allergan Inc. current liabilities increased from 2012 to 2013 and from 2013 to 2014.
Non-current liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Allergan Inc. non-current liabilities increased from 2012 to 2013 and from 2013 to 2014.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Allergan Inc. total liabilities increased from 2012 to 2013 and from 2013 to 2014.
Total Allergan, Inc. stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Allergan Inc. total Allergan, Inc. stockholders’ equity increased from 2012 to 2013 and from 2013 to 2014.